Your browser doesn't support javascript.
loading
Treatment of [99mTc]Tc-hydroxy-diphosphonate ([99mTc]Tc-HDP) extravasation using hyaluronidase.
Doornhof, Kevin R; de Lussanet de la Sablonière, Quido; Koolen, Stijn L W; Konijnenberg, Mark W.
Affiliation
  • Doornhof KR; Department of Radiology and Nuclear Medicine, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • de Lussanet de la Sablonière Q; Department of Radiology and Nuclear Medicine, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Koolen SLW; Department of Radiology and Nuclear Medicine, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Konijnenberg MW; Department of Radiology and Nuclear Medicine, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Pharmacol Res Perspect ; 12(4): e1232, 2024 Aug.
Article de En | MEDLINE | ID: mdl-39054750
ABSTRACT
Extravasation of 99mTc-labeled radiopharmaceuticals is generally considered to require no specific intervention. In the presented case, the use of hyaluronidase could have minimized the adverse effects resulting from such an extravasation. Currently, no guidelines exist regarding the use of hyaluronidase after extravasation of [99mTc]Tc-HDP. Considering the low risk of administering hyaluronidase, it should be considered to limit the risk of injury after extravasation of [99mTc]Tc-HDP.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Radiopharmaceutiques / Extravasation de produits diagnostiques ou thérapeutiques / Hyaluronoglucosaminidase Limites: Humans Langue: En Journal: Pharmacol Res Perspect Année: 2024 Type de document: Article Pays d'affiliation: Pays-Bas Pays de publication: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Radiopharmaceutiques / Extravasation de produits diagnostiques ou thérapeutiques / Hyaluronoglucosaminidase Limites: Humans Langue: En Journal: Pharmacol Res Perspect Année: 2024 Type de document: Article Pays d'affiliation: Pays-Bas Pays de publication: États-Unis d'Amérique